Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.

ABSTRACT:

Importance

Convergent biological, epidemiological, and clinical data identified urate elevation as a candidate strategy for slowing disability progression in Parkinson disease (PD).

Objective

To determine the safety, tolerability, and urate-elevating capability of the urate precursor inosine in early PD and to assess its suitability and potential design features for a disease-modification trial.

Design, setting, and participants

The Safety of Urate Elevation in PD (SURE-PD) study, a randomized, double-blind, placebo-controlled, dose-ranging trial of inosine, enrolled participants from 2009 to 2011 and followed them for up to 25 months at outpatient visits to 17 credentialed clinical study sites of the Parkinson Study Group across the United States. Seventy-five consen

SUBMITTER: Parkinson Study Group SURE-PD Investigators 

PROVIDER: S-EPMC3940333 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature